EPGL Gains Third US Patent Allowance and InWith Corp. Proposes EPGL Buyout Bid

Wednesday, February 1, 2017 Corporate News
Email Print This Page Comment
Font : A-A+

IRVINE, Calif., Jan. 31, 2017 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL)

In a joint

statement, EPGL announces that it has received its third consecutive US Patent allowance in the field of ophthalmic technologies while start-up partner InWith Corp. announces it will make a bid to buyout EPGL. 

For EPGL, the allowed US Patent

titled "Piezoelectric Sensor for Vision Correction" (U.S. 14/622,814), protects the sensing of the vibration of the ciliary muscle within the human eye, to trigger a self-focus mechanism within a soft contact lenses.   EPGL's IP counsel was recently notified of the Allowance by the United States Patent and Trademark Office. 

InWith Corp., a start-up company with plans to make new "body technologies" from wearable devices to implantable devices tied to a mobile wireless network, announced that it is seeking as much as $500 million in private funding. 

InWith Corp. is a private company with 100 million authorized shares.  InWith Corp. and EPGL previously announced a partnership to build EPGL's patented ophthalmic technologies.   Several EPGL shareholders have requested and will receive a gift of Inwith Corp. equity.   As a result, InWith Corp. will have private shareholders from all over the world.  The Company has announced that Dr. Scott Peterson will be its Vice President.  Dr. Peterson has been in practice for over 33 years and specializes in Glaucoma treatment and contact lenses.  The management team of InWith Corp. will be fully announced by end of February 2017.

InWith Corp. will make a bid to buyout EP Global Communications, Inc. (EPGL) if EPGL shareholders allow the full offer to be presented by InWith Corp. via a Proxy Vote.  The offer will involve a choice for EPGL's retail shareholders to be bought out in a cash price of up to 9.8 cents per share, or to receive approximately 125% of their current EPGL equity by percentage (total along with gifted shares) converted to InWith Corp. equity.   The choice would be offered as "one or the other" to EPGL shareholders and they could make their choice individually from other shareholders.  In any event, EPGL shareholders who formally requested the InWith Corp. gift equity offer, will receive that gift equity regardless if a full buyout is finalized.

EPGL will put the InWith Corp. detailed proposal before its shareholders in a Proxy Vote.  The Company notes that other entities who hold first rights to purchase EPGL technologies, will continue to enjoy those rights through to the building of the products, regardless of any completed buyout.

About EP Global Communications, Inc. 

EP Global Communications, Inc. is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).

For more information about EP Global Communications, Inc., visit www.epglmed.com

Email: investors@epglmed.com

About InWith Corporation

InWith Corporation is a privately manufacturer and brander of high technology products in the medical and consumer electronics field. 

Email: info@inwithcorp.com

Website: www.inwithcorp.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epgl-gains-third-us-patent-allowance-and-inwith-corp-proposes-epgl-buyout-bid-300400030.html

SOURCE EP Global Communications, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook